A robust methodology is presented to identify
novel biomaterials suitable for three-dimensional (3D)
printing. Currently, the application of additive manufacturing
is limited by the availability of functional inks, especially in the
area of biomaterials; this is the first time when this method is
used to tackle this problem, allowing hundreds of formulations
to be readily assessed. Several functional properties, including
the release of an antidepressive drug (paroxetine), cytotoxicity, and printability, are screened for 253 new ink formulations in a
high-throughput format as well as mechanical properties. The selected candidates with the desirable properties are successfully
scaled up using 3D printing into a range of object architectures. A full drug release study and degradability and tensile modulus
experiments are presented on a simple architecture to validating the suitability of this methodology to identify printable inks for
3D printing devices with bespoke properties.